Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 2:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 85 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parkinson Disease, Idiopathic Clear all
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

NCT01711866
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease

NCT02462603
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PTC-589
Drug
Lead sponsor
Edison Pharmaceuticals Inc
Industry
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 11, 2026, 2:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring Parkinson's Disease With Tear Fluid

NCT03037463
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
35 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

NCT05357989
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Not applicable Interventional Results available

Voice Treatment for Parkinson's Disease

NCT03700684
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
Lee Silverman Voice Treatment, SpeechVive, Control
Behavioral · Device
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
West Lafayette, Indiana • Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 2 Interventional

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

NCT00163085
View directory record Official record
Conditions
Parkinson's Disease
Interventions
NR2B NMDA Antagonist CP-101,606 (traxoprodil)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 22, 2006 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 1 Interventional

Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease

NCT00006488
View directory record Official record
Conditions
Parkinson Disease
Interventions
recombinant-methionyl human glial cell line-derived neurotrophic factor
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 3 Interventional Results available

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

NCT02352363
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Observational cohort
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 2 Interventional

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

NCT01211587
View directory record Official record
Conditions
Parkinson's Disease With Cognitive Impairments
Interventions
safinamide, placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
45 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
9
States / cities
Sunnyvale, California • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

NCT00985517
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CERE-120: Adeno-Associated Virus Delivery of Neurturin, Sham Surgery
Biological · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
35 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

NCT00505687
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Fort Wayne, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 1 Interventional

Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

NCT00252850
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CERE-120: AAV2-NTN
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
35 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 11, 2026, 2:53 PM EDT
Not listed Phase 2 Interventional

A Study to Evaluate in Patients With Parkinsonian Type Disorders

NCT03683225
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
CTC-413
Combination Product
Lead sponsor
Chase Therapeutics Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 11, 2026, 2:53 PM EDT
Active, not recruiting Not applicable Interventional

ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease

NCT03319485
View directory record Official record
Conditions
Parkinson Disease
Interventions
ExAblate Pallidotomy, Sham ExAblate Pallidotomy
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Stanford, California • Boynton Beach, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 11, 2026, 2:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease

NCT07106021
View directory record Official record
Conditions
Idiopathic Parkinson´s Disease, Parkinson's Disease
Interventions
RNDP-001, Syringe Front-Loading Device
Biological · Device
Lead sponsor
Kenai Therapeutics
Industry
Eligibility
45 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Tucson, Arizona • Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 11, 2026, 2:53 PM EDT
Recruiting Not applicable Interventional

Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease

NCT06859528
View directory record Official record
Conditions
Parkinson Disease, Parkinson Disease, Idiopathic
Interventions
Community Walking Program
Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
30 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 3 Interventional Results available

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02242487
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 86 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

NCT01744496
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Gilbert, Arizona • Sunnyvale, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

NCT04506073
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug
Lead sponsor
Mya Schiess
Other
Eligibility
50 Years to 79 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Not applicable Interventional Results available

ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease

NCT02246374
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ExAblate Transcranial System
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 11, 2026, 2:53 PM EDT
Recruiting Not applicable Interventional

The Impact of Deep Brain Stimulation on Speech and Swallow Function in Parkinson Disease

NCT07026734
View directory record Official record
Conditions
Parkinson Disease, Idiopathic
Interventions
Deep brain stimulation surgery - GPi, Deep Brain Stimulation Surgery - STN
Procedure
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 11, 2026, 2:53 PM EDT
Terminated Phase 3 Interventional Results available

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

NCT00519532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
St. Petersburg, Florida • Salisbury, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 11, 2026, 2:53 PM EDT
Completed Phase 4 Interventional Results available

Lundbeck TOMs Orthostatic Hypotension

NCT04510922
View directory record Official record
Conditions
Orthostatic Hypotension, Idiopathic Parkinson Disease
Interventions
Droxidopa 100 MG [Northera]
Drug
Lead sponsor
Alberto Espay, MD, MSc
Other
Eligibility
30 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 11, 2026, 2:53 PM EDT